RecruitingNCT05817227
Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.
Sponsor
National Cancer Institute, Naples
Enrollment
300 participants
Start Date
May 19, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This is multicentric, spontaneous, observational, retrospective and prospective study.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria2
- TNBC breast cancer patients, before any drug treatment
- healthy women aged 25-60
Exclusion Criteria1
- donors suffering from diabetes, hypertension, active infectious states, HIV infection, Hepatitis B or C, chronic inflammatory diseases, current or previous neoplasms, heart disease or drug treatment.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05817227
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location